Skip to content
2000
Volume 9, Issue 6
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

The prevalences of overweightedness and obesity are increasing globally at frightening rates, driven by social and economic changes. Furthermore, obesity is associated with the pathogeneses of major diseases, particularly diabetes and cardiovascular diseases. However, no satisfactorily safe, effective obesity drugs are commercially available at the present time. Only two drugs have been approved in the United States for the long-term treatment of obesity, sibutramine and orlistat. However, these drugs are minimally effective and have significant side effects, which are likely inhibit their use. Therefore, there is a huge opportunity to make a significant impact on the lives of obese people through the discovery and development of additional pharmacotherapeutic options. In this review article, the authors focus on selected trends in medicinal chemistry and the approaches used to develop drugs for treating obesity.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/156802609788897853
2009-04-01
2025-09-15
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/156802609788897853
Loading

  • Article Type:
    Research Article
Keyword(s): aminergic receptor modulator; Antiobesity; CB1; MC4R; MCH1R; neuropeptide Y family
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test